A heat-stable COVID-19 vaccine that is being developed in India and does not need cold chain storage has generated strong antibody response against coronavirus variants, including Delta and Omicron, according to a study on mice.
The researchers found that loss of smell was less common in participants infected during Omicron prevalence than during Delta wave. Sore throat was more common during Omicron prevalence than during Delta prevalence, they said.
People infected with SARS-CoV-2, the virus that causes COVID-19, have an increased risk of developing serious blood clots for up to six months after the infection, even in mild cases, according to a study published in The BMJ.